Associations

Associations

Kairos Pharma Presents Positive Interim Efficacy Data on Combination Therapy of ENV-105 and Apalutamide in Metastatic Castration-Resistant Prostate Cancer

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, has presented positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the European Society of Medical Oncologists meeting in Berlin, Germany. The data highlights the potential value of combination